Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Forecast Ownership Financials Chart Transcripts

Previous Close

$1.57

52W Range

$0.85 - $3.49

50D Avg

$1.22

200D Avg

$1.60

Market Cap

$88.44M

Avg Vol (3M)

$446.88K

Beta

0.11

Div Yield

-

ABOS Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

61

IPO Date

Jul 01, 2021

Website

ABOS Performance

ABOS Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-114.02M	$-61.14M	$-45.24M
Net Income	$-102.33M	$-52.37M	$-40.48M
EBITDA	$-114.02M	$-51.61M	$-42.69M
Basic EPS	$-1.71	$-1.08	$-1.00
Diluted EPS	$-1.71	$-1.08	$-1.00

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 13, 25 | 8:00 AM

Q4 24Mar 27, 25 | 8:00 AM

Q3 24Nov 12, 24 | 8:00 AM

Peer Comparison

Ticker	Company
TERN	Terns Pharmaceuticals, Inc.
AMLX	Amylyx Pharmaceuticals, Inc.
MREO	Mereo BioPharma Group plc
DAWN	Day One Biopharmaceuticals, Inc.
XFOR	X4 Pharmaceuticals, Inc.
HOOK	HOOKIPA Pharma Inc.
INZY	Inozyme Pharma, Inc.